Literature DB >> 28116801

Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.

S C Lin1,2, E Heba3, R Bettencourt2,4, G Y Lin5, M A Valasek5, O Lunde6, G Hamilton3, C B Sirlin3, R Loomba2,4,7.   

Abstract

BACKGROUND: Magnetic resonance imaging-derived measures of liver fat and volume are emerging as accurate, non-invasive imaging biomarkers in non-alcoholic steatohepatitis (NASH). Little is known about these measures in relation to histology longitudinally. AIM: To examine any relationship between MRI-derived proton-density fat-fraction (PDFF), total liver volume (TLV), total liver fat index (TLFI), vs. histology in a NASH trial.
METHODS: This is a secondary analysis of a 24-week randomised, double-blind, placebo-controlled trial of 50 patients with biopsy-proven NASH randomised to oral ezetimibe 10 mg daily (n = 25) vs. placebo (n = 25). Baseline and post-treatment anthropometrics, biochemical profiling, MRI and biopsies were obtained.
RESULTS: Baseline mean PDFF correlated strongly with TLFI (Spearman's ρ = 0.94, n = 45, P < 0.0001) and had good correlation with TLV (ρ = 0.57, n = 45, P < 0.0001). Mean TLV correlated strongly with TLFI (ρ = 0.78, n = 45, P < 0.0001). After 24 weeks, PDFF remained strongly correlated with TLFI (ρ = 0.94, n = 45, P < 0.0001), maintaining good correlation with TLV (ρ = 0.51, n = 45, P = 0.0004). TLV remained strongly correlated with TLFI (ρ = 0.74, n = 45, P < 0.0001). Patients with Grade 1 vs. 3 steatosis had lower PDFF, TLV, and TLFI (P < 0.0001, P = 0.0003, P < 0.0001 respectively). Regression analysis of changes in MRI-PDFF vs. TLV indicates that 10% reduction in MRI-PDFF predicts 257 mL reduction in TLV.
CONCLUSIONS: The MRI-PDFF and TLV strongly correlated with TLFI. Decreases in steatosis were associated with an improvement in hepatomegaly. Lower values of these measures reflect lower histologic steatosis grades. MRI-derived measures of liver fat and volume may be used as dynamic and more responsive imaging biomarkers in a NASH trial, than histology.
© 2017 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28116801      PMCID: PMC5346270          DOI: 10.1111/apt.13951

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  41 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 2.  Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis.

Authors:  Leon A Adams; Ariel E Feldstein
Journal:  J Dig Dis       Date:  2011-02       Impact factor: 2.325

Review 3.  Liver fat content determined by magnetic resonance imaging and spectroscopy.

Authors:  Fabian Springer; Jürgen Machann; Claus D Claussen; Fritz Schick; Nina F Schwenzer
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

Review 4.  Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.

Authors:  Brad Q Starley; Christopher J Calcagno; Stephen A Harrison
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

5.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

Authors:  Leon A Adams; James F Lymp; Jenny St Sauver; Schuyler O Sanderson; Keith D Lindor; Ariel Feldstein; Paul Angulo
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

6.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Authors:  Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison
Journal:  Gastroenterology       Date:  2010-09-19       Impact factor: 22.682

Review 7.  Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance.

Authors:  Nina F Schwenzer; Fabian Springer; Christina Schraml; Norbert Stefan; Jürgen Machann; Fritz Schick
Journal:  J Hepatol       Date:  2009-06-11       Impact factor: 25.083

Review 8.  The epidemiology of obesity.

Authors:  Cynthia L Ogden; Susan Z Yanovski; Margaret D Carroll; Katherine M Flegal
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

9.  Ultrasonographic evaluation of liver volume and the metabolic syndrome in obese women.

Authors:  F Santini; M Giannetti; S Mazzeo; P Fierabracci; G Scartabelli; A Marsili; R Valeriano; A Pucci; M Anselmino; V Zampa; P Vitti; A Pinchera
Journal:  J Endocrinol Invest       Date:  2007-02       Impact factor: 4.256

10.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

Authors:  A Michael Lincoff; Kathy Wolski; Stephen J Nicholls; Steven E Nissen
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

View more
  7 in total

1.  Liver volume and hepatic adiposity in childhood: relations to body growth and visceral fat.

Authors:  R Malpique; J Bassols; A López-Bermejo; M Diaz; F Villarroya; J Pavia; A Congo; F de Zegher; L Ibáñez
Journal:  Int J Obes (Lond)       Date:  2017-08-14       Impact factor: 5.095

Review 2.  Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging.

Authors:  Yingzhen N Zhang; Kathryn J Fowler; Gavin Hamilton; Jennifer Y Cui; Ethan Z Sy; Michelle Balanay; Jonathan C Hooker; Nikolaus Szeverenyi; Claude B Sirlin
Journal:  Br J Radiol       Date:  2018-06-06       Impact factor: 3.039

3.  MRI liver fat quantification in an oncologic population: the added value of complex chemical shift-encoded MRI.

Authors:  Giuseppe Corrias; Simone Krebs; Sarah Eskreis-Winkler; Davinia Ryan; Junting Zheng; Marinela Capanu; Luca Saba; Serena Monti; Maggie Fung; Scott Reeder; Lorenzo Mannelli
Journal:  Clin Imaging       Date:  2018-08-08       Impact factor: 1.605

4.  Si-Wei-Qing-Gan-Tang Improves Non-Alcoholic Steatohepatitis by Modulating the Nuclear Factor-κB Signal Pathway and Autophagy in Methionine and Choline Deficient Diet-Fed Rats.

Authors:  Lingyun Xiao; Shu Liang; Lanlan Ge; Shuling Qiu; Haoqiang Wan; Shipin Wu; Jia Fei; Shusong Peng; Xiaobin Zeng
Journal:  Front Pharmacol       Date:  2020-05-01       Impact factor: 5.810

5.  Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial.

Authors:  Magnus Holmer; Catarina Lindqvist; Sven Petersson; John Moshtaghi-Svensson; Veronika Tillander; Torkel B Brismar; Hannes Hagström; Per Stål
Journal:  JHEP Rep       Date:  2021-02-17

6.  Role of Magnetic Resonance Imaging in the Monitoring of Patients with Nonalcoholic Fatty Liver Disease: Comparison with Ultrasonography, Lipid Profile, and Body Mass Index.

Authors:  Nikhil Makhija; Naval K Vikram; Gurdeep Kaur; Raju Sharma; Deep N Srivastava; Kumble S Madhusudhan
Journal:  J Clin Exp Hepatol       Date:  2019-09-20

7.  Relationship Between Histological Features of Non-alcoholic Fatty Liver Disease and Ectopic Fat on Magnetic Resonance Imaging in Children and Adolescents.

Authors:  Eun Hye Lee; Ji Young Kim; Hye Ran Yang
Journal:  Front Pediatr       Date:  2021-06-10       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.